Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 84,293,296
  • Shares Outstanding, K 335,870
  • Annual Sales, $ 14,571 M
  • Annual Income, $ 14,973 M
  • 36-Month Beta 1.16
  • Price/Sales 5.74
  • Price/Cash Flow 7.66
  • Price/Book 1.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
239.16 +6.46%
on 07/07/17
256.80 -0.85%
on 07/25/17
+8.16 (+3.31%)
since 06/23/17
3-Month
218.60 +16.48%
on 05/18/17
256.80 -0.85%
on 07/25/17
+16.40 (+6.88%)
since 04/25/17
52-Week
184.50 +38.01%
on 11/23/16
261.27 -2.55%
on 07/27/16
+6.77 (+2.73%)
since 07/25/16

Most Recent Stories

More News
Ophthalmic Drugs Market to Reach US$34.3 Billion by 2025: Players Entering Into Co-development Agreements to Enhance Product Portfolio

ALBANY, New York, July 25, 2017 /PRNewswire/ --

VRX.TO : 22.16 (+1.14%)
BAYRY : 130.0100 (-0.13%)
AERI : 55.95 (-2.86%)
SNPHF : 13.2500 (-0.69%)
AGN : 254.62 (+0.43%)
NVS : 84.20 (-0.11%)
REGN : 513.45 (-1.49%)
PFE : 33.10 (-0.66%)
Histogen's Growth Factor Technology to be Marketed as Part of Allergan Skin Care Line

Histogen, Inc., a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, today announced that its proprietary multipotent cell...

AGN : 254.62 (+0.43%)
Pawar Law Group Announces Filing of Securities Class Action Lawsuit Against Allergan, Inc. - AGN

NEW YORK, NY / ACCESSWIRE / July 24, 2017 / The Pawar Law Group announces a class action lawsuit on behalf of Allergan, Inc. (NYSE: AGN) investors who purchased Allergan stock between February 25, 2014...

AGN : 254.62 (+0.43%)
Look for Shares of Allergan Plc to Potentially Pullback after Yesterday's 1.35% Rise

Allergan Plc (NYSE:AGN) traded in a range yesterday that spanned from a low of $249.40 to a high of $254.39. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $251.79...

AGN : 254.62 (+0.43%)
Renowned Houston Cosmetic Surgeon Meets With Allergan's Newly Formed Management Team

Paul Vitenas, MD, FACS is excited to report that he was among an elite group of the nation's top level plastic surgeons, invited to attend Allergan's recent meeting with their Plastics Advisory Board....

AGN : 254.62 (+0.43%)
Global Cystic Fibrosis Therapeutics Market 2016-2022: Profiles of Key players - Genentech, Novartis, Vertex, Abbott, Gilead Sciences & Allergan

DUBLIN, July 24, 2017 /PRNewswire/ --

AGN : 254.62 (+0.43%)
NVS : 84.20 (-0.11%)
GILD : 73.74 (-0.87%)
Global Cystic Fibrosis Therapeutics Market 2016-2022: Profiles of Key players - Genentech, Novartis, Vertex, Abbott, Gilead Sciences & Allergan

The "Global Cystic Fibrosis Therapeutics Market Outlook 2022" report has been added to Research and Markets' offering.

AGN : 254.62 (+0.43%)
NVS : 84.20 (-0.11%)
GILD : 73.74 (-0.87%)
Fort Worth Plastic Surgeon Joins Allergan Advisory Board

Board certified plastic surgeon Dr. Emily J. Kirby, medical director of Kirby Plastic Surgery in Fort Worth, was recently selected to serve as a consultant for the global pharmaceutical manufacturer Allergan,...

AGN : 254.62 (+0.43%)
Investigational New Drug Application for RTGel(TM) in Combination with BOTOX(R) for the Treatment of Overactive Bladder Submitted to FDA by Allergan

UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it...

URGN : 18.99 (+1.55%)
AGN : 254.62 (+0.43%)
Joseph H. Boccuzi Appointed to Allergan plc Board of Directors

Allergan plc (NYSE: AGN) today announced that Joseph H. Boccuzi has been appointed to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences,...

AGN : 254.62 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Support & Resistance

2nd Resistance Point 258.85
1st Resistance Point 256.73
Last Price 254.62
1st Support Level 252.57
2nd Support Level 250.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.